Physician profile
Albert E Weeks
NPI 1336147263
$12,596.84
in general payments reported to CMS, 2019-2025
64 companies · $761 in 2025
The $761 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,396 · 2020: $1,052 · 2021: $1,411 · 2022: $2,009 · 2023: $2,207 · 2024: $2,762 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,499 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,498.80 |
| Education | $231.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $738.23 | 2019-2025 | Carvykti, Rybrevant, Darzalex |
| Eisai INC. | $731.91 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $725.53 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Pfizer INC. | $708.01 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $655.74 | 2019-2024 | Lynparza, Imfinzi, Calquence |
| Novartis Pharmaceuticals Corporation | $634.42 | 2019-2025 | Kisqali |
| Glaxosmithkline, LLC. | $603.79 | 2020-2024 | Ojjaara, Jemperli, Zejula |
| Amgen INC. | $561.14 | 2019-2024 | Blincyto, Kyprolis, Prolia |
| Abbvie INC. | $556.23 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $550.75 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Merck Sharp & Dohme LLC | $532.55 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $503.82 | 2021-2025 | Trodelvy |
| Lilly USA, LLC | $455.83 | 2019-2024 | Jaypirca, Verzenio |
| Daiichi Sankyo INC. | $321.57 | 2020-2025 | Enhertu, Injectafer |
| Celgene Corporation | $294.27 | 2019-2024 | Reblozyl, Opdualag |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.